Trevi Therapeutics Set for Financial Results Announcement
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, is gearing up to report its financial performance for the fourth quarter and the entire year of 2024. This significant event will take place during a conference call and a live audio webcast scheduled for March 18, 2025, at 4:30 p.m. ET. It promises to be an insightful session as senior management will also provide updated information about the company’s developments.
How to Join the Conference Call
For those interested in participating, there are two options available. You can join the live conference call by dialing (877) 870 4263 if you're calling domestically or (412) 317 0790 for international calls. There is no access code needed—just ask to join the Trevi Therapeutics call. Additionally, a live audio webcast will be accessible from the 'Investors & News' section of their official website, making it convenient for viewers globally.
About Trevi Therapeutics and Haduvio™
Trevi Therapeutics focuses on developing Haduvio™, an investigational oral therapy aimed at treating chronic cough associated with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). This unique approach involves targeting both the central and peripheral cough reflex arcs through the combination of a kappa agonist and a mu antagonist, crucial in managing cough hypersensitivity.
Understanding Chronic Cough's Impact
Chronic cough is notably troubling, affecting up to 85% of the IPF patient population. With approximately 140,000 individuals diagnosed with IPF in the U.S., many suffer from coughing fits as frequent as 1,500 times a day. This persistent cough can result in serious complications, including deterioration of the condition, increased mortality rates, and possible lung transplants, all of which significantly impair the quality of life.
Refractory chronic cough, a condition marked by a cough lasting over eight weeks despite treatment for underlying issues, poses additional challenges, impacting around 2-3 million adults in the U.S. Those affected often encounter major difficulties, from social embarrassment to sleep interruptions, presenting not just health issues but also social and economic burdens on individuals and their families.
The Future of Haduvio™
Trevi Therapeutics plans to propose the name Haduvio for their oral nalbuphine ER therapy, and this name may soon become synonymous with hope for patients suffering from chronic cough. However, it's crucial to note that the therapy's safety and efficacy are yet to be evaluated by regulatory authorities, meaning further developments will be closely observed by stakeholders.
Company Contacts and Information
For those wanting to reach out for more details, the investor contact is Jonathan Carlson from Trevi Therapeutics at (203) 654 3286. For media inquiries, Rosalia Scampoli can be contacted at 914-815-1465. While specific emails have been redacted for privacy, it’s clear that Trevi maintains solid lines of communication for both investors and the media.
Frequently Asked Questions
When will Trevi Therapeutics announce its financial results?
Trevi Therapeutics will announce its financial results for the fourth quarter and year-end 2024 on March 18, 2025.
How can I join the Trevi Therapeutics conference call?
You can join by dialing (877) 870 4263 for domestic calls or (412) 317 0790 for international calls. No access code is necessary.
What is Haduvio™ and what does it treat?
Haduvio™ is an investigational oral therapy under development for treating chronic cough in patients with IPF and RCC.
What percentage of IPF patients suffer from chronic cough?
Approximately 85% of patients with idiopathic pulmonary fibrosis experience chronic cough.
Who can I contact for investor or media inquiries?
Investor inquiries can be addressed to Jonathan Carlson, while media inquiries can be directed to Rosalia Scampoli at Trevi Therapeutics.
